<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> may respond to intravenous <z:chebi fb="1" ids="29864">mannitol</z:chebi>, but frequent administration can cause <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> or renal problems </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the use of 20% <z:chebi fb="3" ids="17754">glycerol</z:chebi> administered intravenously as an alternative to <z:chebi fb="1" ids="29864">mannitol</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Intravenous <z:chebi fb="3" ids="17754">glycerol</z:chebi> and <z:chebi fb="1" ids="29864">mannitol</z:chebi> were equally effective in lowering <z:hpo ids='HP_0011009'>acute</z:hpo> elevations of intracranial pressure </plain></SENT>
<SENT sid="3" pm="."><plain>The duration of effect was similar for both agents </plain></SENT>
<SENT sid="4" pm="."><plain>Side effects of intravenous <z:chebi fb="3" ids="17754">glycerol</z:chebi> were related to concentration, rate, and frequency of administration </plain></SENT>
<SENT sid="5" pm="."><plain>In severe <z:hpo ids='HP_0001298'>encephalopathies</z:hpo>, such as <z:e sem="disease" ids="C0035400" disease_type="Disease or Syndrome" abbrv="">Reye syndrome</z:e>, we recommend infusions of 20% <z:chebi fb="3" ids="17754">glycerol</z:chebi> or 20% <z:chebi fb="1" ids="29864">mannitol</z:chebi> at a dose of 0.5-1.0 gm per kilogram </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="3" ids="17754">Glycerol</z:chebi> should be administered in 0.45% or 0.9% saline, no faster than 1.5 ml (3.3 mOsm) per minute </plain></SENT>
</text></document>